Prof Xavier Leleu discusses the significance of minimal residual disease (MRD) in newly diagnosed multiple myeloma. He emphasises the importance of achieving deep response and whether MRD negativity should be a treatment goal for patients with newly diagnosed multiple myeloma.

Additionally, he examines the clinical relevance of MRD and progression-free survival (PFS) in clinical trials for newly diagnosed multiple myeloma. Prof Leleu also analyses the important abstracts related to the treatment of newly diagnosed multiple myeloma from ASCO 2024.